Study: NCT02373930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AS
Description: DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AM
Description: DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AQ
Description: DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTG/RPV 50 mg/25 mg: Product Code AK
Description: DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally